Noveris Health Sciences Receives USPTO Notice of Allowance, and Signs Work Order with API
Rhea-AI Summary
Noveris Health Sciences (OTC Pink: MYCOF) announced that the USPTO has issued a Notice of Allowance for U.S. Patent Application No. 18/443,025, covering six claims on aza-substituted psilocin analogs and related pharmaceutical compositions. The examiner distinguished the claimed compounds from prior art based on the R2 substituent, and the application stems from a patent family originating in December 2021.
The Notice of Allowance completes substantive examination but is not yet a granted patent; issuance depends on meeting USPTO requirements and paying issue and publication fees, which Noveris intends to do. The company also signed a work order and provided $146,000 in funding to Applied Pharmaceutical Innovation to restart synthesis and in vitro evaluation of promising psilocybin-related compounds, generate data to guide future R&D decisions, and enable potential rapid GMP scale-up if further clinical development is warranted.
Positive
- USPTO Notice of Allowance for U.S. Patent Application No. 18/443,025 with six allowable claims
- $146,000 work order funding to Applied Pharmaceutical Innovation to restart synthesis and evaluations
- API engagement structured for potential rapid GMP scale-up of selected molecules if development proceeds
Negative
- Notice of Allowance is not yet a granted patent and remains subject to USPTO requirements and fee payments
- Management cautions there is no assurance initial API work will justify further development of any compound
- Regulatory note emphasizes no drug candidate approvals yet and no assurance of future regulatory approval or commercialization
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - August 18, 2026) - Noveris Health Sciences Inc. (CSE: NVRS) (FSE: 0NF1) (OTC Pink: MYCOF) ("Noveris" or the "Company") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued a Notice of Allowance for the Company's U.S. Patent Application No. 18/443,025, titled "Aza-Substituted Psilocin Analogs and Methods of Synthesizing the Same."
The Notice of Allowance confirms that all six claims in the application have been found allowable, with prosecution on the merits now closed. The allowed claims cover aza-substituted psilocin analog compounds, including species incorporating dimethylamine and diisopropylamine substituents, together with corresponding pharmaceutical compositions.
In its Statement of Reasons for Allowance, the USPTO examiner distinguished the claimed compounds from the cited prior art based on the substituent at the R2 position. The application forms part of a patent family originating from a PCT application filed in December 2021 and continued through subsequent U.S. applications.
Noveris' aza-substituted psilocin analogs were designed to investigate potential improvements in chemical stability, pharmacokinetic properties and delivery options relative to naturally occurring psilocybin and psilocin, including potential transdermal and transmucosal routes of administration.
A Notice of Allowance indicates that the USPTO has completed substantive examination of the allowed claims. A Notice of Allowance is not itself a grant of patent rights, and issuance remains subject to satisfaction of the applicable USPTO requirements, including payment of required fees. The Company intends to pay the applicable issue and publication fees within the prescribed period to advance U.S. Patent Application No. 18/443,025 toward issuance.
Research Program with Applied Pharmaceutical Innovation
As previously announced on June 5, 2026, the Company has re-engaged Applied Pharmaceutical Innovation ("API") to provide research and development services focused on psilocybin product development, the discovery of novel products, and the identification and protection of related intellectual property. API is one of Canada's largest life sciences commercialization organizations, with operations at multiple sites in Alberta.
The Company is pleased to announce today that it has signed a work order and provided funding to API in the amount of
Pursuant to the work order, API will support Noveris in restarting the synthesis of promising compounds, chemistry, in vitro evaluation, quality and project-management activities intended to generate information that may assist Noveris in determining appropriate next steps for compounds under review. API will conduct the work in a framework that will ensure the rapid scale-up of selected molecules in stage appropriate GMP if rapid development towards clinical testing is warranted.
"These are important developments for Noveris because it brings two parts of our work together," said Jason Birmingham, President and Chief Executive Officer of Noveris. "We are continuing to protect intellectual property developed over several years while putting selected compounds back into active research. The work with API gives us an opportunity to generate new information and make disciplined decisions about which compounds, if any, warrant further investment and development."
"We're very pleased to be working with Noveris on their novel pipeline of molecules. With our teams' experience and infrastructure, we'll be able to ensure the organization is able to transition from discovery to rapid derisking as they move forward in this exciting area of the pharmaceutical sector." Andrew MacIsaac, CEO, Applied Pharmaceutical Innovation.
Noveris will review the results of the initial work before determining which compounds, if any, should advance into additional research and development. Management notes that there can be no assurance that the initial work will produce results sufficient to support further development of any compound.
About Noveris Health Sciences Inc.
Noveris Health Sciences Inc. is a biotechnology company focused on the development, advancement and commercialization of intellectual property, technologies and therapeutic opportunities addressing unmet needs in healthcare. The Company continues to evaluate opportunities involving its existing intellectual property portfolio, research collaborations, strategic partnerships, licensing arrangements and related commercial initiatives.
For Further Information
Noveris Health Sciences Inc.
Jason Birmingham
President & Chief Executive Officer
Telephone: +1 (778) 900-6877
Email: fair@noveris.health
Website: www.noveris.health
Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including National Instrument 51-102 Continuous Disclosure Obligations. Forward-looking statements in this news release include, but are not limited to, statements regarding the Company's intention to complete the requirements necessary to advance U.S. Patent Application No. 18/443,025 toward issuance; the scope, timing and potential outcomes of the work order with API; the synthesis and evaluation of previously investigated compounds; the generation of additional research information; the Company's determination of future research and development priorities; and the potential advancement, protection, licensing, partnering or commercialization of the Company's intellectual property and compounds. Forward-looking statements are based on assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions, and expected future developments, as well as other factors the Company believes are appropriate in the circumstances.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, the possibility that U.S. Patent Application No. 18/443,025 does not proceed to issuance as anticipated; that the scope of any issued patent may differ from expectations; that additional patent applications may not result in allowed or issued claims; that the API work may not proceed as planned; that anticipated research results may not be achieved; that previously investigated compounds may not demonstrate characteristics sufficient to justify further development; that timelines, costs and research priorities may change; and that the Company may be unable to successfully protect, develop, license or commercialize its intellectual property or compounds. A Notice of Allowance is not a guarantee that a patent will issue. Early-stage research results, if any, may not result in successful development, regulatory approval or commercialization.
Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws.
Additional Regulatory Note — Life Sciences
The Company's drug development programs are subject to regulatory oversight by Health Canada and other applicable regulatory authorities. This re-engagement with API does not constitute approval of any drug candidate, nor does it represent a change in the regulatory status of any compound in the Company's pipeline. There can be no assurance that any drug candidate will receive regulatory approval or be successfully commercialized.
Exchange Disclaimer
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/310360